Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Idiopathic erythrocytosis--a declining entity.
Blacklock HA, Royle GA. Blacklock HA, et al. Br J Haematol. 2001 Dec;115(4):774-81. doi: 10.1046/j.1365-2141.2001.03168.x. Br J Haematol. 2001. PMID: 11843808 Free article. Review. No abstract available.
Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study.
Quach H, Fernyhough L, Henderson R, Corbett G, Baker B, Browett P, Blacklock H, Forsyth C, Underhill C, Cannell P, Trotman J, Neylon A, Harrison S, Link E, Swern A, Cowan L, Dimopoulos MA, Miles Prince H. Quach H, et al. Br J Haematol. 2017 May;177(3):441-448. doi: 10.1111/bjh.14562. Epub 2017 Feb 15. Br J Haematol. 2017. PMID: 28197996 Free article. Clinical Trial.
Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR).
McQuilten Z, Wellard C, Moore E, Augustson B, Bergin K, Blacklock H, Harrison S, Ho PJ, King T, Quach H, Mollee P, Rosengarten B, Walker P, Wood E, Spencer A; Australian and New Zealand Myeloma and Related Diseases Registry. McQuilten Z, et al. Br J Haematol. 2022 Sep;198(5):830-837. doi: 10.1111/bjh.18324. Epub 2022 Jul 11. Br J Haematol. 2022. PMID: 35818641 Free PMC article.
Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction.
Boyle S, Wellard C, Moore EM, Blacklock H, Harrison SJ, Ho PJ, Hocking J, McQuilten ZK, Quach H, Spearing R, Wood EM, Spencer A, Mollee P; Myeloma and Related Diseases Registry investigators. Boyle S, et al. Eur J Haematol. 2021 Oct;107(4):497-499. doi: 10.1111/ejh.13677. Epub 2021 Jun 26. Eur J Haematol. 2021. PMID: 34129711 No abstract available.
89 results